Study of immune resistance after immunotherapy
Part of Cancer clinical trials.
This trial studies why some solid cancers stop responding to immune-based drugs (like anti–PD-1/PD-L1) and what can be done next. You may be eligible if your cancer has progressed after immunotherapy and you can safely undergo a tumor needle biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed solid cancer diagnosis (found on biopsy/scan test called histology or cytology).
- At least one tumor spot can be safely reached with a core needle biopsy, and you agree to that procedure.
- Your cancer must have progressed after an anti–PD-1 or anti–PD-L1 immunotherapy dose (or be hard to respond from the start).
- You’re at least 18 years old and can do usual daily activities fairly well (ECOG 0–1).
- You can give written consent, and nothing serious prevents safe blood draws or study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the bacteria in your gut may affect how well immunotherapy works for solid cancers that have spread or cannot be removed. It focuses on people who have been on certain immunotherapy drugs (PD-1 or PD-L1 inhibitors) for at least 3 months but less than 2 years.
This study looks at side effects from immune checkpoint inhibitors in people with solid tumors. It aims to understand why side effects happen and who might be at risk, so doctors can better manage them.
This trial studies how well immunotherapy might work by analyzing fresh tumor biopsies. It may help predict which treatments are best for your cancer.
This study looks at lung tumor tissue and blood to understand why immune checkpoint drugs can stop working in non-small cell lung cancer. It may help researchers find better ways to predict and overcome drug resistance.
This study looks at how well immunotherapy drugs (like checkpoint inhibitors) work for different cancers. If you are already planning to receive this type of treatment, researchers want to track your outcomes and see how you do over time.
This study looks at preserved tissue samples from people with lung cancer to understand why some tumors don't respond to immunotherapy drugs like PD-1/PD-L1 inhibitors. The goal is to find patterns that could help predict treatment success.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.